EsoBiotec’s platform has the potential to eliminate the complex and time-consuming process for manufacturing, helping to make CAR-T cell therapies more accessible.

INmune Bio's high-upside potential with CORDStrom for RDEB and XPro for Alzheimer's, offering up to 144.8x returns. Click ...

The British Army's Land Rover and Pinzgauer vehicles are to be replaced by 2030 by a group of vehicles called the Light ...